New research is showing that exposure to dim light at night may negatively impact the effectiveness of breast cancer treatments. In a laboratory setting, dim light exposure during night cycles made human breast tumors in rats more resistant to doxorubicin, a standard chemotherapy for breast cancer.
But why? Well, it’s all about melatonin. Melatonin is a hormone that is produced naturally by the body during dark periods at night. In this research study, exposure to light at night disrupted rats’ melatonin cycles. Half of the rats, however, received melatonin supplements to make up for this. Researchers found that the tumors grew almost three times faster in rats that did not receive supplements, and their tumors were completely resistant to doxorubicin. It seems that the presence of melatonin helped support higher levels of active doxorubicin in the breast cancer cells, and prevented enzymes from breaking it down and making it less effective.
At this point, researchers aren’t ready to make supplementation recommendations for human breast cancer patients. And if the effects of melatonin ARE similar in humans, recommendations for supplementation would need to be carefully monitored. If disrupting the natural melatonin cycle can cause the body to react to cancer treatments differently, then incorrectly supplementing could also cause undesired effects. However, since this isn’t the first time that dim light exposure at night has been shown to have negative effects, it’s possible that this research could prompt patients to be more aware of light exposure disruptions during night cycles.
Read more about it here: http://www.aacr.org/Newsroom/Pages/News-Release-Detail.aspx?ItemID=608#.VC9VpPldWSo
It’s pretty likely that you’ve injured yourself at some point or another and experienced a break in your skin that caused bleeding. Skinned knees, paper cuts, hangnails- we’ve all been there. Initially, these injuries can bleed quite a bit, but after a few minutes the bleeding slows and eventually stops.
This type of drug could make a huge difference to patients currently taking blood thinners. The next steps will likely include human trials to determine if results in animals are an indication of the drug’s chances for success in humans. Read more about it here:
A pill intended for leukemia treatment may soon make a big difference for patients suffering from a variety of cancers. These drugs worked so well against leukemia that during trials, patients taking placebo pills were switched over to the real drug!
Cancer cells produce an enzyme called p110. This enzyme suppresses immunity, making it hard for the body to fight back against disease. The drug works by blocking that enzyme so the body can fight back more efficiently.
It turns out that this pill could be effective against a wider range of cancers than previously thought. Through research in mice with a variety of cancers, survival rate was greatly increased. Mouse studies indicate that this could be an effective treatment against breast cancer by not only minimizing the spread of the disease, but also by improving survival rates after removal of breast tumors!
P110 inhibitors could quickly become part of cancer treatments, as the drugs are already being successfully used on cancer patients. It will be interesting to see if administration of this drug for other types of cancer will be as successful as animal trials. Read more about it here: